z-logo
Premium
A comparison of terbinafine (Lamisil®) 1% cream given for one week with clotrimazole (Canesten®) 1% cream given for four weeks, in the treatment of tinea pedis
Author(s) -
EVANS E.G.V.
Publication year - 1994
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1994.tb06086.x
Subject(s) - clotrimazole , terbinafine , medicine , dermatology , tinea capitis , antifungal , itraconazole
Summary Terbinafine (Lamisil®) is a synthetic allylamine antifungal which has been shown to be fungicidal against dermatophytes and a number of yeasts and moulds. Topical application of terbinafine 1% cream has been shown to be a highly effective short‐duration therapy for dermatophytosis of the skin. The aim of this multicentre, double‐blind, parallel‐group study was to compare the safety and efficacy of terbinafine 1% cream, applied twice daily for 1 week, with clotrimazole (Canesten®) 1% cream, applied twice daily for 4 weeks, in the treatment of tinea pedis. One hundred and seven patients with mycologically proven tinea pedis received 1 week of terbinafine 1% cream, followed by 3 weeks of placebo, and 104 patients received clotrimazole 1% cream for 4 weeks. Mycological cure (negative microscopy and culture) and effective treatment (mycological cure with no or minimal signs and symptoms) were assessed 4 and 6 weeks after commencing therapy. Mycological cure rates were 93·5% for terbinafine and 73·1% for clotrimazole (p = 0·000l) at 4 weeks, and 97·2% for terbinafine and 83·7% for clotrimazole (P = 0·0001) at 6 weeks. Effective treatment rates at 4 weeks were 89·7% for terbinafine and 58·7% for clotrimazole (P = 0·0001), and 89·7% for terbinafine and 73·1% for clotrimazole (P = 0·002) at 6 weeks. The results show that 1 week of terbinafine b.d. is more effective than 4 weeks of clotrimazole b.d., in terms of both mycological cure and effective treatment.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here